| Document and Entity Information | Oct. 27, 2022 |
| Cover [Abstract] | |
| Entity Registrant Name | ACORDA THERAPEUTICS INC |
| Amendment Flag | true |
| Entity Central Index Key | 0001008848 |
| Document Type | 8-K/A |
| Document Period End Date | Oct. 27, 2022 |
| Entity Incorporation State Country Code | DE |
| Entity File Number | 001-31938 |
| Entity Tax Identification Number | 13-3831168 |
| Entity Address, Address Line One | 2 Blue Hill Plaza |
| Entity Address, Address Line Two | 3rd Floor |
| Entity Address, City or Town | Pearl River |
| Entity Address, State or Province | NY |
| Entity Address, Postal Zip Code | 10965 |
| City Area Code | (914) |
| Local Phone Number | 347-4300 |
| Written Communications | false |
| Soliciting Material | true |
| Pre Commencement Tender Offer | false |
| Pre Commencement Issuer Tender Offer | false |
| Security 12b Title | Common Stock, $0.001 par value per share |
| Trading Symbol | ACOR |
| Security Exchange Name | NASDAQ |
| Entity Emerging Growth Company | false |
| Amendment Description | On October 27, 2022, Acorda Therapeutics, Inc. (the “Company”) filed a Current Report on Form 8-K to announce, among other things, its long-term business plan (the “Original 8-K”). This amendment is being filed by the Company solely for the purpose of updating the Original 8-K as further described below. |
